Telix Pharmaceuticals Ltd (TLX)

Telix and United Imaging Announce Strategic Theranostics Collaboration

Partnership to evaluate Telix’s innovative precision medicine products and candidates in combination with...

ProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026

Telix’s first-in-class lutetium radio antibody-drug conjugate (rADC) candidate, TLX591-Tx, demonstrates...

Telix to Participate in William Blair Growth Stock and Jefferies Global Healthcare Conferences

MELBOURNE, Australia and INDIANAPOLIS, May 27, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:...

IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing

IPAX-2 study of TLX101-Tx (¹³¹I-iodofalan) has completed patient enrolment.Maximum dose reached with no...

Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches

Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies...

Form 4 - Statement of changes in beneficial ownership of securities

New Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCC

MELBOURNE, Australia and INDIANAPOLIS, May 05, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:...

TLX101-Px (Pixlumi®) MAA Accepted in Europe

TLX101-Px (Pixlumi®) MAA Accepted in Europe PR Newswire MELBOURNE, Australia and INDIANAPOLIS, May 1, 2026...

TLX101-Px (Pixlumi®) MAA Accepted in Europe

MELBOURNE, Australia and INDIANAPOLIS, May 01, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:...

OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer

TLX597-Tx is a PSMA1-targeting small molecule radioligand therapy (RLT) candidate, designed to improve...

Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach

MELBOURNE, Australia and INDIANAPOLIS, April 28, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:...

ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026

MELBOURNE, Australia and INDIANAPOLIS, April 22, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:...

Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma

MELBOURNE, Australia and INDIANAPOLIS, April 15, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:...

Telix Successfully Prices and Upsizes US$600 Million Convertible Bonds

Telix Successfully Prices and Upsizes US$600 Million Convertible Bonds PR Newswire MELBOURNE, Australia and...

Telix Refinances Convertible Bonds

Telix Refinances Convertible Bonds PR Newswire MELBOURNE, Australia and INDIANAPOLIS, Ind., April 14, 2026...